Inhibition of Janus Kinase 1 synergizes docetaxel sensitivity in prostate cancer cells
Open Access
- 28 July 2021
- journal article
- research article
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 25 (17) , 8187-8200
Abstract
Prostate cancer (PCa) is the second most common malignancy and is the fifth leading cause of cancer mortality among men globally. Docetaxel-based therapy remains the first-line treatment for metastatic castration-resistant prostate cancer. However, dose-limiting toxicity including neutropenia, myelosuppression and neurotoxicity is the major reason for docetaxel dose reductions and fewer cycles administered, despite a recent study showing a clear survival benefit with increased total number of docetaxel cycles in PCa patients. Although previous studies have attempted to improve the efficacy and reduce docetaxel toxicity through drug combination, no drug has yet demonstrated improved overall survival in clinical trial, highlighting the challenges of improving the activity of docetaxel monotherapy in PCa. Herein, we identified 15 lethality hits for which inhibition could enhance docetaxel sensitivity in PCa cells via a high-throughput kinome-wide loss-of-function screen. Further drug-gene interactions analyses identified Janus kinase 1 (JAK1) as a viable druggable target with existing experimental inhibitors and FDA-approved drugs. We demonstrated that depletion of endogenous JAK1 enhanced docetaxel-induced apoptosis in PCa cells. Furthermore, inhibition of JAK1/2 by baricitinib and ruxolitinib synergizes docetaxel sensitivity in both androgen receptor (AR)–negative DU145 and PC3 cells, but not in the AR-positive LNCaP cells. In contrast, no synergistic effects were observed in cells treated with JAK2-specific inhibitor, fedratinib, suggesting that the synergistic effects are mainly mediated through JAK1 inhibition. In conclusion, the combination therapy with JAK1 inhibitors and docetaxel could be a useful therapeutic strategy in the treatment of prostate cancers.Keywords
Funding Information
- Ministry of Higher Education, Malaysia (ERGS/1/2013/SKK01/IMU/02/1, FRGS/1/2016/SKK08/IMU/01/1)
This publication has 81 references indexed in Scilit:
- Global cancer transitions according to the Human Development Index (2008–2030): a population-based studyThe Lancet Oncology, 2012
- Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone With or Without Bevacizumab in Men With Metastatic Castration-Resistant Prostate Cancer: CALGB 90401Journal of Clinical Oncology, 2012
- Antiangiogenic and Antimetastatic Activity of JAK Inhibitor AZD1480Cancer Research, 2011
- The JAK2 Inhibitor AZD1480 Potently Blocks Stat3 Signaling and Oncogenesis in Solid TumorsCancer Cell, 2009
- Endoglin phosphorylation by ALK2 contributes to the regulation of prostate cancer cell migrationCarcinogenesis, 2009
- Depletion of intrinsic expression of Interleukin-8 in prostate cancer cells causes cell cycle arrest, spontaneous apoptosis and increases the efficacy of chemotherapeutic drugsMolecular Cancer, 2009
- The High-Mobility Group A1a/Signal Transducer and Activator of Transcription-3 Axis: An Achilles Heel for Hematopoietic Malignancies?Cancer Research, 2008
- The PIM1 Kinase Is a Critical Component of a Survival Pathway Activated by Docetaxel and Promotes Survival of Docetaxel-treated Prostate Cancer CellsJournal of Biological Chemistry, 2008
- Expression levels of the JAK/STAT pathway in the transition from hormone-sensitive to hormone-refractory prostate cancerBritish Journal of Cancer, 2007
- Endoglin inhibits prostate cancer motility via activation of the ALK2-Smad1 pathwayOncogene, 2007